Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com

Listen by Clicking below:

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].

Lancet Respiratory Medicine has reported the results of the COLCORONA trial, showing that in patients with PCR-confirmed COVID-19 infection, colchicine led to a significantly lower rate of death or hospital admission from COVID.

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.

A large prospective cohort study examined the comparative risks of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) and found that, methotrexate (MTX), abatacept (ABA) and TNF inhibitor (TNFi) use were associated with a decreased risk of CV events. 

JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.

House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.

Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com